Chauhan R, Raina V, Nandi SP. Prevalence of autoimmune diseases and its challenges in diagnosis. Crit Rev Immunol. 2019;39(3):189–201. https://doi.org/10.1615/CritRevImmunol.2019031798.

Article  PubMed  Google Scholar 

Lenti MV, Rossi CM, Melazzini F, et al. Seronegative autoimmune diseases: a challenging diagnosis. Autoimmun Rev. 2022;21(9): 103143. https://doi.org/10.1016/j.autrev.2022.103143.

Article  CAS  PubMed  Google Scholar 

Siddle HJ, Bradley SH, Anderson AM, Mankia K, Emery P, Richards SH. Opportunities and challenges in early diagnosis of rheumatoid arthritis in general practice. Br J Gen Pract. 2023;73(729):152–4. https://doi.org/10.3399/bjgp23X732321.

Article  PubMed  PubMed Central  Google Scholar 

Monti S, Montecucco C, Bugatti S, Caporali R. Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. RMD Open. 2015;1(Suppl 1): e000057. https://doi.org/10.1136/rmdopen-2015-000057.

Article  PubMed  PubMed Central  Google Scholar 

Clarke AE, Weinstein A, Piscitello A, et al. Evaluation of the economic benefit of earlier systemic lupus erythematosus (SLE) diagnosis using a multivariate assay panel (MAP). ACR Open Rheumatol. 2020;2(11):629–39. https://doi.org/10.1002/acr2.11177.

Article  PubMed  PubMed Central  Google Scholar 

Rachid B, El Zorkany B, Youseif E, Tikly M. Early diagnosis and treatment of ankylosing spondylitis in Africa and the Middle East. Clin Rheumatol. 2012;31(11):1633–9. https://doi.org/10.1007/s10067-012-2058-5.

Article  PubMed  Google Scholar 

Hioki T, Komine M, Ohtsuki M. Diagnosis and intervention in early psoriatic arthritis. J Clin Med. 2022. https://doi.org/10.3390/jcm11072051.

Article  PubMed  PubMed Central  Google Scholar 

Steyers CM 3rd, Miller FJ Jr. Endothelial dysfunction in chronic inflammatory diseases. Int J Mol Sci. 2014;15(7):11324–49. https://doi.org/10.3390/ijms150711324.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Atehortua L, Rojas M, Vasquez G, et al. Endothelial activation and injury by microparticles in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther. 2019;21(1):34. https://doi.org/10.1186/s13075-018-1796-4.

Article  PubMed  PubMed Central  Google Scholar 

Wienke J, Mertens JS, Garcia S, et al. Biomarker profiles of endothelial activation and dysfunction in rare systemic autoimmune diseases: implications for cardiovascular risk. Rheumatology (Oxford). 2021;60(2):785–801. https://doi.org/10.1093/rheumatology/keaa270.

Article  CAS  PubMed  Google Scholar 

McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3(8): e297. https://doi.org/10.1371/journal.pmed.0030297.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moutsopoulos HM. Autoimmune rheumatic diseases: one or many diseases? J Transl Autoimmun. 2021;4: 100129. https://doi.org/10.1016/j.jtauto.2021.100129.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Torsney E, Charlton R, Parums D, Collis M, Arthur HM. Inducible expression of human endoglin during inflammation and wound healing in vivo. Inflamm Res. 2002;51(9):464–70. https://doi.org/10.1007/pl00012413.

Article  CAS  PubMed  Google Scholar 

Shao Y, Saredy J, Yang WY, et al. Vascular endothelial cells and innate immunity. Arterioscler Thromb Vasc Biol. 2020;40(6):e138–52. https://doi.org/10.1161/ATVBAHA.120.314330.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Amersfoort J, Eelen G, Carmeliet P. Immunomodulation by endothelial cells - partnering up with the immune system? Nat Rev Immunol. 2022;22(9):576–88. https://doi.org/10.1038/s41577-022-00694-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmidt-Weber CB, Letarte M, Kunzmann S, Ruckert B, Bernabeu C, Blaser K. TGF-beta signaling of human T cells is modulated by the ancillary TGF-beta receptor endoglin. Int Immunol. 2005;17(7):921–30. https://doi.org/10.1093/intimm/dxh272.

Article  CAS  PubMed  Google Scholar 

Lastres P, Bellon T, Cabanas C, et al. Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. Eur J Immunol. 1992;22(2):393–7. https://doi.org/10.1002/eji.1830220216.

Article  CAS  PubMed  Google Scholar 

Schoonderwoerd MJA, Koops MFM, Angela RA, et al. Targeting endoglin-expressing regulatory T cells in the tumor microenvironment enhances the effect of PD1 checkpoint inhibitor immunotherapy. Clin Cancer Res. 2020;26(14):3831–42. https://doi.org/10.1158/1078-0432.CCR-19-2889.

Article  CAS  PubMed  Google Scholar 

Meurer SK, Weiskirchen R. Endoglin: an ‘accessory’ receptor regulating blood cell development and inflammation. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21239247.

Article  PubMed  PubMed Central  Google Scholar 

Schoonderwoerd MJA, Goumans MTH, Hawinkels L. Endoglin: beyond the endothelium. Biomolecules. 2020. https://doi.org/10.3390/biom10020289.

Article  PubMed  PubMed Central  Google Scholar 

Lopez-Novoa JM, Bernabeu C. The physiological role of endoglin in the cardiovascular system. Am J Physiol Heart Circ Physiol. 2010;299(4):H959–74. https://doi.org/10.1152/ajpheart.01251.2009.

Article  CAS  PubMed  Google Scholar 

Gonzalez Munoz T, Amaral AT, Puerto-Camacho P, Peinado H, de Alava E. Endoglin in the spotlight to treat cancer. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22063186.

Article  PubMed  PubMed Central  Google Scholar 

Rossi E, Bernabeu C. Novel vascular roles of human endoglin in pathophysiology. J Thromb Haemost. 2023;21(9):2327–38. https://doi.org/10.1016/j.jtha.2023.06.007.

Article  PubMed  Google Scholar 

Vicen M, Igreja Sa IC, Tripska K, et al. Membrane and soluble endoglin role in cardiovascular and metabolic disorders related to metabolic syndrome. Cell Mol Life Sci. 2021;78(6):2405–18. https://doi.org/10.1007/s00018-020-03701-w.

Article  CAS  PubMed  Google Scholar 

Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12(6):642–9. https://doi.org/10.1038/nm1429.

Article  CAS  PubMed  Google Scholar 

Haarmann A, Vollmuth C, Kollikowski AM, et al. Vasoactive soluble endoglin: a novel biomarker indicative of reperfusion after cerebral large-vessel occlusion. Cells. 2023. https://doi.org/10.3390/cells12020288.

Article  PubMed  PubMed Central  Google Scholar 

Igreja Sa IC, Tripska K, Hroch M, et al. Soluble endoglin as a potential biomarker of nonalcoholic steatohepatitis (NASH) development, participating in aggravation of NASH-related changes in mouse liver. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21239021.

Article  PubMed  PubMed Central  Google Scholar 

Moola S, Munn Z, Tufanaru C, et al. Systematic reviews of etiology and risk. In: Aromataris E, Munn Z, editors. Joanna Briggs Institute Reviewer’s Manual. Adelaide, Australia: Johanna Briggs Institute; 2017.

Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401–6. https://doi.org/10.1016/j.jclinepi.2010.07.015.

Article  PubMed